J Am Heart Assoc:巨噬细胞NCOR1缺陷或可改善心肌梗死和血管内膜新生的情况

2021-07-09 MedSci原创 MedSci原创

NCOR1(核受体核心压迫因子1)是基因转录的一个重要核心调节因子。已有研究表明,巨噬细胞中的NCOR1在代谢调节中发挥重要作用。然而,巨噬细胞NCOR1在应对心肌梗死(MI)或血管损伤中的功能还没有

NCOR1(核受体核心压迫因子1)是基因转录的一个重要核心调节因子。已有研究表明,巨噬细胞中的NCOR1在代谢调节中发挥重要作用。然而,巨噬细胞NCOR1在应对心肌梗死(MI)或血管损伤中的功能还没有被阐释。

 

本文中,研究人员利用巨噬细胞NCOR1基因敲除小鼠,结合小鼠MI模型,证明巨噬细胞NCOR1的缺失能明显减少梗死面积,改善MI后的心脏功能。此外,巨噬细胞NCOR1的缺乏明显抑制了动脉线损伤小鼠模型中的新内膜增生和血管重塑。该研究结果已发表于J Am Heart Assoc。

MI和动脉线损伤后,巨噬细胞NCOR1基因敲除小鼠的心脏和动脉中炎症和巨噬细胞增殖显著减弱。来自巨噬细胞Ncor1基因敲除小鼠的培养的原代巨噬细胞在白细胞介素-1β、白细胞介素-6或脂多糖刺激时表现出较低水平的炎症基因表达,同时炎症信号级联的激活也较少,包括信号转导和转录激活因子1以及核因子-κB。此外,与对照组细胞相比,巨噬细胞Ncor1基因敲除的巨噬细胞在培养中的增殖能力大大降低,其细胞周期进程受到抑制。

总之,该研究结果表明,NCOR1是巨噬细胞炎症和增殖的一个关键调节器,巨噬细胞中NCOR1的缺失会减弱MI和新内膜增生。因此,巨噬细胞NCOR1可作为MI和再狭窄的潜在治疗靶点。

 

原始出处:

 

Lin-Juan Du, et al., Macrophage NCOR1 Deficiency Ameliorates Myocardial Infarction and Neointimal Hyperplasia in Mice. J Am Heart Assoc. 2020 Aug 4;9(15):e015862. doi: 10.1161/JAHA.120.015862. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708652, encodeId=6d281e08652b7, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sun Jan 23 10:03:04 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357736, encodeId=0854135e7365b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 11 07:03:04 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563485, encodeId=74b6156348588, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jul 11 07:03:04 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998160, encodeId=d11f9981605d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abe25434876, createdName=ms6000000196724174, createdTime=Sat Jul 10 10:36:07 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708652, encodeId=6d281e08652b7, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sun Jan 23 10:03:04 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357736, encodeId=0854135e7365b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 11 07:03:04 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563485, encodeId=74b6156348588, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jul 11 07:03:04 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998160, encodeId=d11f9981605d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abe25434876, createdName=ms6000000196724174, createdTime=Sat Jul 10 10:36:07 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2021-07-11 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1708652, encodeId=6d281e08652b7, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sun Jan 23 10:03:04 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357736, encodeId=0854135e7365b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 11 07:03:04 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563485, encodeId=74b6156348588, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jul 11 07:03:04 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998160, encodeId=d11f9981605d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abe25434876, createdName=ms6000000196724174, createdTime=Sat Jul 10 10:36:07 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2021-07-11 slcumt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1708652, encodeId=6d281e08652b7, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sun Jan 23 10:03:04 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357736, encodeId=0854135e7365b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 11 07:03:04 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563485, encodeId=74b6156348588, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jul 11 07:03:04 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998160, encodeId=d11f9981605d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abe25434876, createdName=ms6000000196724174, createdTime=Sat Jul 10 10:36:07 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2021-07-10 ms6000000196724174

    谢谢分享

    0

相关资讯

JAHA:血清尿酸累积量及其时间变化与心肌梗死和全因死亡率相关

MI的风险和全因死亡率随着cumSUA的增加而增加,并受SUA积累时间过程的影响。在总体累积暴露相同的情况下,早期SUA积累比后期SUA积累对MI风险和全因死亡率的贡献更大。

Radiology:对于心肌梗死的评估,不要只知道超声!

左心房(LA)的大小是不同心脏疾病的重要预后预测因子。指南建议评估最大LA线性尺寸、面积或容积,这是左心室(LV)充盈压力升高的标志。

Circulation:高敏心肌肌钙蛋白对早期排除心肌梗死的临床意义

对疑似急性冠脉综合征的患者进行早期排除筛查可减轻患者的医疗负担和医务工作者的工作量,且不增加漏诊率

Circulation:抑制脑啡肽酶对MI后左室收缩功能障碍患者的心室重构的影响

在心肌梗死后出现无症状左心室功能减退的患者中,与缬沙坦相比,Sacubitril/缬沙坦治疗没有显著的抗心室重构效果

Eur Heart J:选择性冠脉重建相比药物治疗可进一步改善冠心病患者预后

对于稳定性冠状动脉疾病患者,与单纯药物治疗相比,选择性冠状动脉重建联合药物治疗可降低心源性死亡率

梅斯心血管疾病进展 (006期)

编者按:梅斯医学将定期进行汇总,帮助大家概览心血管领域最新进展。下面是呈现给大家的最新一期的心血管进展。enjoy~